Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
Ryan Allway May 25th, 2021 Psychedelics DENVER, May 25, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today... Read more
Tryp Therapeutics Partners with Alcami for Proprietary Formulations
Ryan Allway May 25th, 2021 Psychedelics San Diego, California–(Newsfile Corp. – May 25, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (“Alcami”),... Read more
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
Ryan Allway May 25th, 2021 Psychedelics TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive... Read more
Ryan Allway May 24th, 2021 Psychedelics, Top News With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and... Read more
Filament Announces C$10M Offering and Filing of Initial Listing Application
Ryan Allway May 21st, 2021 Psychedelics VANCOUVER, BC, May 17, 2021 /CNW/ – Filament Ventures Corp. (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery and extraction company, is pleased to announce that it has entered into an agreement with Echelon Wealth Partners Inc. and Canaccord Genuity Corp. (together,... Read more
Wake Network Successfully Completes First Legal Psilocybin Mushroom Import into The United States
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products
Ryan Allway May 19th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – May 19, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce it has entered into a production and supply agreement (the “Agreement”) on May 14, 2021 with HAVN Life Sciences Inc. (CSE:... Read more
HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings
Natural Health Products Will Be Manufactured and Packaged at the Company’s New Facility VANCOUVER, BC / ACCESSWIRE / May 19, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased... Read more
Novamind Opens Client Care Center to Support High Demand for Treatments
Ryan Allway May 18th, 2021 Psychedelics Invests in care support systems to facilitate rapid expansion TORONTO, ON / ACCESSWIRE / May 18, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, has opened a new Novamind Client Care Center (“Client... Read more
Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group
Ryan Allway May 18th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – May 18, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the “Agreement“)... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )